38 results on '"Barros, Scott A."'
Search Results
2. Genotoxicity Tests for Novel Oligonucleotide-Based Therapeutics
3. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
4. Safety profile of RNAi nanomedicines
5. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
6. Discovery and Development Strategies for Small Interfering RNAs
7. Activation of Protein Kinase Cζ Increases OAT1 (SLC22A6)- and OAT3 (SLC22A8)-mediated Transport
8. The flounder organic anion transporter fOat has sequence, function, and substrate specificity similarity to both mammalian Oat1 and Oat3
9. Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions
10. Predictive Toxicogenomics in Preclinical Discovery
11. Toxicogenomics strategies for predicting drug toxicity
12. The importance of applying toxicogenomics to increase the efficiency of drug discovery
13. Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
14. Impact of Oligonucleotide Structure, Chemistry, and Delivery Method onIn VitroCytotoxicity
15. Exposure to siRNA-GalNAc Conjugates in Systems of the Standard Test Battery for Genotoxicity
16. OSWG Recommendations for Genotoxicity Testing of Novel Oligonucleotide-Based Therapeutics
17. 279 Pre-Clinical Evaluation of ALN-AAT to Ameliorate Liver Disease Associated With Alpha-1-Antitrypsin Deficiency
18. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
19. A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B
20. Impact of Oligonucleotide Structure, Chemistry, and Delivery Method on In Vitro Cytotoxicity.
21. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
22. 850c RNAi Therapeutics Ameliorate Liver Disease Associated with Alpha-1-Antitrypsin Deficiency
23. Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy
24. Correction for Dong et al., Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
25. Expanded Therapeutic Index Of Antithrombin Silencing and Correction Of Aptt In a Hemophilia A Mouse Model
26. Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
27. An RNAi Therapeutic Targeting Antithrombin Increases Thrombin Generation in Nonhuman Primates
28. Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein Particles
29. Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo
30. Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells
31. Rational design of cationic lipids for siRNA delivery
32. Molecular structure and characterization of a novel murine ABC transporter, Abca13
33. Predictive Toxicogenomics in Preclinical Discovery.
34. Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions
35. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates.
36. RNAi-Mediated Inhibition of a Natural Anticoagulant for the Treatment of Hemophilia.
37. Recent Advances in Lipid Nanoparticle-Mediated Delivery of RNAi Therapeutics.
38. Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.